Application of compound aureomycin A in aspect of inhibiting kidney inflammation

A technology of aureotomycin and its compounds, applied in the field of medicine, can solve problems such as kidney system diseases that have not yet been treated with aureotomycin A

Pending Publication Date: 2022-04-22
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are few reports on the pharmacological activity of aureotomycin A, and there is no report on the use of aureonomycin A in inhibiting renal inflammation and related renal system diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound aureomycin A in aspect of inhibiting kidney inflammation
  • Application of compound aureomycin A in aspect of inhibiting kidney inflammation
  • Application of compound aureomycin A in aspect of inhibiting kidney inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0028] Effects of aureotomycin A on LPS-induced renal tissue inflammation in mice

[0029] 1. Experimental method

[0030] 1.1 Animal grouping and administration

[0031] Reagent LPS (Sigma Company); IL-1β, IL-6, TNF-α, MCP-1 detection ELISA kit (Gitai Yikesai Biotechnology Co., Ltd.).

[0032] Experimental Animals Adult male BALB / c mice, weighing 20-22 g, were purchased from Speiford (Beijing) Biotechnology Co., Ltd., animal quality certificate number: SYXK (Beijing) 2016-0002. Raise under normal conditions, temperature (25±1°C), relative humidity 55%-65%, 12h photoperiod, free access to food and water.

[0033] Animal grouping and administration Animals were randomly divided into groups after 3 days of adaptation: normal control group, LPS model group, aureonomycin A 3mg / kg administration group (LPS+Chr-A 3mg / kg), aureonomycin A 10mg / kg administration group (LPS+Chr-A 10mg / kg). The solvent control group and the LPS model group were given intraperitoneal injection of the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines, discloses application of Chrysomycin A in preparation of medicines for inhibiting kidney inflammation, and particularly discloses application of Chrysomycin A (Chr-A) as shown in a general formula (I) in preparation of medicines for inhibiting kidney inflammation and related renal failure, infectious renal injury and other diseases. Pharmacological experiments prove that the aureomycin A can significantly inhibit the increase of the levels of LPS-induced kidney tissue inflammatory factors interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor (TNF alpha) and monocyte chemotactic factor (MCP-1), and shows that the aureomycin A has significant activity of inhibiting the inflammatory response of the kidney tissue.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the use of aureotomycin A in the preparation of medicines for inhibiting renal inflammation and related diseases such as renal failure and infectious renal injury. Background technique [0002] Acute kidney injury is a common clinical critical emergency and an important cause of death in patients. Lipopolysaccharide-induced sepsis is a common cause of acute kidney injury. The mortality rate of sepsis patients with acute kidney injury is twice as high as that of patients with simple sepsis. Protecting renal function can help reduce sepsis patient mortality and improved patient outcomes. [0003] Lipopolysaccharide (LPS) can be used to prepare inflammatory response models. When exogenous LPS enters the body, it forms LPS-binding proteins that act on receptors on the cell membrane and activates downstream inflammatory pathways to mediate inflammatory responses, releasing a large ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P13/12A61P29/00
CPCA61K31/7048A61P13/12A61P29/00
Inventor 王月华杜冠华刘漫杨滢霖张姗姗刘冬妮
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap